Top Markets
#1 BOOK OF MEME BOOK OF MEME +26.80%
#2 XPIN Network XPIN Network +23.44%
#3 SSV Network SSV Network +22.92%
#4 The Black Bull The Black Bull +19.80%
#5 Binance-Peg Bitcoin Cash Binance-Peg Bitcoin Cash +17.07%
#6 Bitcoin Cash Bitcoin Cash +16.56%
#7 Mubarak Mubarak +16.49%
#8 Geodnet Geodnet +16.21%
#9 Neiro Neiro +15.03%
#10 Derive Derive +13.77%
Coin of the day
BOOK OF MEME BOOK OF MEME
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Sirnaomics Ltd. Sirnaomics Ltd.

Sirnaomics Ltd.

2257
Classifica tra le azioni #25196
Sirnaomics Ltd. is an RNA therapeutics biopharmaceutical company, founded in... Sirnaomics Ltd. is an RNA therapeutics biopharmaceutical company, founded in 2007 and headquartered in Gaithersburg, Maryland. The company is dedicated to identifying and developing innovative therapeutic compounds aimed at addressing significant medical needs across the United States and the People's Republic of China. Its leading pipeline assets include STP705, which is being investigated for conditions such as cutaneous squamous cell carcinoma in situ, basal cell carcinoma, various liver-related cancers (cholangiocarcinoma, hepatocellular carcinoma, liver metastases), as well as for keloid scar remodeling, hypertrophic scarring, and fat sculpting. Another prominent candidate, STP707, is designed to treat cholangiocarcinoma, hepatocellular carcinoma, liver metastases, metastatic cutaneous squamous cell carcinoma, non-small cell lung cancer, and both liver and lung fibrosis. Beyond these lead programs, Sirnaomics is advancing STP355 for a range of cancers; STP369 for head and neck/bladder cancers; STP779 for liver, lung, and pancreatic cancers; and STP902 for breast cancer. The company's portfolio also extends to infectious diseases with STP702 for influenza, STP908 for COVID-19, the RIM730 COVID-19 vaccine, and STP909 for HPV/cervical cancer. Furthermore, its developmental pipeline encompasses STP122G for thrombotic disorders, STP125G for hypertriglyceridemia, STP144G for complement-mediated ailments, STP133G for cardiometabolic conditions, and STP155G for hepatitis B virus.
Prezzo delle azioni
$0.48164226
Capitalizzazione di mercato
$52.45M
Variazione (1 giorno)
-3.46%
Variazione (1 anno)
-61.91%
Paese
US
Scambia Sirnaomics Ltd. (2257)

Categoria

Healthcare
Ricavi di Sirnaomics Ltd. (2257)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Sirnaomics Ltd., i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Sirnaomics Ltd. da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US